2024
Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma.
Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Editor's Note: Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Research 2024, 84: 3909. PMID: 39544086, DOI: 10.1158/0008-5472.can-24-3017.Peer-Reviewed Original ResearchPortal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities
Gupta V, Sehrawat T, Pinzani M, Strazzabosco M. Portal Fibrosis and the Ductular Reaction: Pathophysiological Role in the Progression of Liver Disease and Translational Opportunities. Gastroenterology 2024 PMID: 39251168, DOI: 10.1053/j.gastro.2024.07.044.Peer-Reviewed Original ResearchLiver diseasePortal fibrosisDuctular reactionPathological repairProgression of liver diseaseCholestatic liver diseaseTranslational opportunitiesChronic liver diseaseProgression of fibrosisCell typesChronic human liver diseaseHuman liver diseaseTumor microenvironmentTherapeutic advancesImmune modulationHistological abnormalitiesVascular changesLiver repairPathophysiological roleFibrosisTreatment prospectsPortal spacesMesenchymal cellsVascular cellsComplex crosstalk396 Introduction of CFTR mutations in isogenic induced pluripotent stem cell–derived cholangiocytes and three-dimensional organoids provides pathophysiological information relevant for treatment of CF-related liver disease
Taleb S, Zaman S, Strazzabosco M, Fiorotto R. 396 Introduction of CFTR mutations in isogenic induced pluripotent stem cell–derived cholangiocytes and three-dimensional organoids provides pathophysiological information relevant for treatment of CF-related liver disease. Journal Of Cystic Fibrosis 2024, 23: s208. DOI: 10.1016/s1569-1993(24)01236-0.Peer-Reviewed Original ResearchTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making
Sobirey R, Matuschewski N, Gross M, Lin M, Kao T, Kasolowsky V, Strazzabosco M, Stein S, Savic L, Gebauer B, Jaffe A, Duncan J, Madoff D, Chapiro J. Tumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making. European Radiology 2024, 1-11. PMID: 39033181, DOI: 10.1007/s00330-024-10955-6.Peer-Reviewed Original ResearchMedian overall survivalTumor response criteriaTumor response assessmentHepatocellular carcinoma patientsHepatocellular carcinomaTumor responseOverall survivalResponse criteriaResponse assessmentNon-respondersPoorer median overall survivalPrediction of tumor responsePredictive valueHepatocellular carcinoma immunotherapyDisease controlPrognostic of survivalClinical baseline parametersLog-rank testKaplan-Meier curvesMultivariate Cox regressionPredicting overall survivalCox regression modelsSurvival benefitStratify patientsMRI pre-Cost-effectiveness analysis: The missing factor in the management of HCC
Njei B, Yi I, Strazzabosco M. Cost-effectiveness analysis: The missing factor in the management of HCC. Clinical Liver Disease 2024, 23: e0178. PMID: 38860130, PMCID: PMC11164007, DOI: 10.1097/cld.0000000000000178.Peer-Reviewed Original ResearchFRI-162 Analysis of cellular crosstalk in fibrocystic liver disease (PKHD1-/-mouse) reveals a central role for cholangiocytes, neutrophils and chronic biliary infection in disease pathogenesis
Syeda Z, Bauer-Pisani T, Taleb S, Fiorotto R, Strazzabosco M. FRI-162 Analysis of cellular crosstalk in fibrocystic liver disease (PKHD1-/-mouse) reveals a central role for cholangiocytes, neutrophils and chronic biliary infection in disease pathogenesis. Journal Of Hepatology 2024, 80: s697. DOI: 10.1016/s0168-8278(24)01983-4.Peer-Reviewed Original ResearchFRI-155 Introduction of class I-III mutations of CFTR in isogenic human iPSCs-derived cholangiocytes and 3D organoids provides pathophysiological information relevant for treatment of cystic fibrosis-related liver disease (CFLD)
Taleb S, Zaman S, Syeda Z, Strazzabosco M, Fiorotto R. FRI-155 Introduction of class I-III mutations of CFTR in isogenic human iPSCs-derived cholangiocytes and 3D organoids provides pathophysiological information relevant for treatment of cystic fibrosis-related liver disease (CFLD). Journal Of Hepatology 2024, 80: s695. DOI: 10.1016/s0168-8278(24)01978-0.Peer-Reviewed Original ResearchNovel updates in the field of HCC
Jaffe A, Strazzabosco M. Novel updates in the field of HCC. Clinical Liver Disease 2024, 23: e0142. PMCID: PMC11078519, DOI: 10.1097/cld.0000000000000142.Peer-Reviewed Original ResearchApproach to immunotherapy for HCC in the liver transplant population
Block P, Strazzabosco M, Jaffe A. Approach to immunotherapy for HCC in the liver transplant population. Clinical Liver Disease 2024, 23: e0158. PMID: 38707244, PMCID: PMC11068135, DOI: 10.1097/cld.0000000000000158.Peer-Reviewed Original ResearchProminent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice
Bertolini A, Nguyen M, Zehra S, Taleb S, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice. Journal Of Hepatology 2024, 81: 429-440. PMID: 38554847, PMCID: PMC11347101, DOI: 10.1016/j.jhep.2024.03.041.Peer-Reviewed Original ResearchCystic fibrosis-related liver diseaseCystic fibrosis transmembrane conductance regulatorCFTR-KO miceDefective cystic fibrosis transmembrane conductance regulatorCFTR-KOIntestinal permeabilityLiver diseaseGut-liver axisGut dysbiosisIncreased morbidityMortality of CF patientsAssociated with increased intestinal permeabilityLiver pathologyDevelopment of cholangiopathyCftr-knockout miceTransmembrane conductance regulatorIncreased intestinal permeabilityTargeted therapeutic strategiesFecal microbiota transferAttenuates liver diseaseExcessive inflammatory responseFITC-dextran assayPresence of neutrophilsActivation of pro-inflammatoryCFTR-knockoutAutomated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning
Gross M, Haider S, Ze’evi T, Huber S, Arora S, Kucukkaya A, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning. European Radiology 2024, 34: 6940-6952. PMID: 38536464, PMCID: PMC11399284, DOI: 10.1007/s00330-024-10624-8.Peer-Reviewed Original ResearchContrast-enhanced magnetic resonance imagingMagnetic resonance imagingClinical staging systemTime of diagnosisHepatocellular carcinomaClinical dataMortality risk predictionOverall survivalStaging systemRadiomic featuresManagement of hepatocellular carcinomaPersonalized follow-up strategiesAssociated with OSMethodsThis retrospective studyHepatocellular carcinoma patientsBaseline magnetic resonance imagingMRI radiomics featuresIndependent validation cohortHarrell's C-indexRisk predictionFollow-up strategiesHigh-risk groupPredictive risk scoreRadiomics feature extractionMedian timeMay we actually help clinicians select the best systemic treatment for patients with intermediate‐stage hepatocellular carcinoma?
Giannini E, Strazzabosco M. May we actually help clinicians select the best systemic treatment for patients with intermediate‐stage hepatocellular carcinoma? Liver International 2024, 44: 272-274. PMID: 38289589, DOI: 10.1111/liv.15781.Peer-Reviewed Original ResearchEuropean Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care
Carbone M, Neuberger J, Rowe I, Polak W, Forsberg A, Fondevila C, Mantovani L, Nardi A, Colli A, Rockell K, Schick L, Cristoferi L, Oniscu G, Strazzabosco M, Cillo U. European Society for Organ Transplantation (ESOT) Consensus Statement on Outcome Measures in Liver Transplantation According to Value-Based Health Care. Transplant International 2024, 36: 12190. PMID: 38332850, PMCID: PMC10850237, DOI: 10.3389/ti.2023.12190.Peer-Reviewed Original ResearchConceptsValue-based health careOutcome measuresEuropean Society of Organ TransplantationLiver transplantationDevelopment of outcome measuresConsensus statementOrgan transplantationValue-basedPatient-focusedAdvanced liver diseaseHealth careMultidisciplinary teamLiver diseaseTransplantationLife-savingEuropean Society for Organ TransplantationPatientsAutomated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics
Gross M, Huber S, Arora S, Ze’evi T, Haider S, Kucukkaya A, Iseke S, Kuhn T, Gebauer B, Michallek F, Dewey M, Vilgrain V, Sartoris R, Ronot M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey J. Automated MRI liver segmentation for anatomical segmentation, liver volumetry, and the extraction of radiomics. European Radiology 2024, 34: 5056-5065. PMID: 38217704, PMCID: PMC11245591, DOI: 10.1007/s00330-023-10495-5.Peer-Reviewed Original ResearchMagnetic resonance imagingRadiomics feature extractionLiver volumetryIntraclass correlation coefficientRadiomic featuresLiver segmentationAutomated liver volumetryHepatocellular carcinoma patientsMann-Whitney U testAutomated liver segmentationManual segmentationQuantitative imaging biomarkersCarcinoma patientsRetrospective studyInstitutional databaseAnatomical localizationClinical relevanceManual volumetryMann-WhitneyU testExternal validationInternal test setImaging biomarkersInclusion criteriaResultsIn total
2023
Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.
Mezzacappa C, Rossi R, Jaffe A, Taddei T, Strazzabosco M. Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study. Cancer Epidemiology Biomarkers & Prevention 2023, 33: 270-278. PMID: 38059831, PMCID: PMC10872555, DOI: 10.1158/1055-9965.epi-23-0902.Peer-Reviewed Original ResearchSafety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis. Liver Cancer 2023, 13: 235-245. PMID: 38756146, PMCID: PMC11095597, DOI: 10.1159/000533991.Peer-Reviewed Original ResearchChild-Pugh class B patientsChild-Pugh B patientsClass B patientsObjective response rateProgression-free survivalChild-Pugh AB patientsOverall survivalHepatocellular carcinomaAdverse eventsLiver functionOdds ratioChild-Pugh class A patientsTreatment-related adverse eventsChild-Pugh class AHigher objective response rateShorter progression-free survivalMedian overall survivalAlbumin-bilirubin gradeImpaired liver functionClass A patientsUnresectable hepatocellular carcinomaIndividualization of treatmentChild-PughALBI gradeIt could happen in your backyard
Strazzabosco M. It could happen in your backyard. Hepatology 2023, 79: 749-751. PMID: 37722133, DOI: 10.1097/hep.0000000000000596.Peer-Reviewed Original ResearchSystematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma
Pasta A, Calabrese F, Jaffe A, Labanca S, Marenco S, Pieri G, Torres M, Strazzabosco M, Giannini E. Systematic review and meta-analysis of safety and efficacy of atezolizumab/ bevacizumab in Child-Pugh class B patients with hepatocellular carcinoma. Digestive And Liver Disease 2023, 55: s221. DOI: 10.1016/j.dld.2023.08.025.Peer-Reviewed Original ResearchChild-Pugh class B patientsClass B patientsDisease control rateObjective response rateImpaired liver functionB patientsHepatocellular carcinomaLiver functionChild-Pugh B cirrhosisTreatment-related adverse eventsHigher objective response rateAdverse events gradeBest supportive careMedian overall survivalProgression-free survivalIndividualization of treatmentClass AB cirrhosisChild-PughCohort studyFree survivalOverall survivalSupportive careAdverse eventsOncological efficacySAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma
Cadamuro M, Sarcognato S, Camerotto R, Girardi N, Lasagni A, Zanus G, Cillo U, Gringeri E, Morana G, Strazzabosco M, Campello E, Simioni P, Guido M, Fabris L. SAT-283 Intrahepatic cholangiocarcinoma developing in patients with metabolic syndrome is characterized by Osteopontin overexpression in the tumor stroma. Journal Of Hepatology 2023, 78: s564-s565. DOI: 10.1016/s0168-8278(23)01358-2.Peer-Reviewed Original ResearchOS-099 Gender differences in repair mechanisms of chronic cholangiopathies with progressive fibrosis
Cadamuro M, Haxhiaj L, Montanaro C, Villa E, Floreani A, Cazzagon N, Baggio G, Strazzabosco M, Simioni P, Fabris L. OS-099 Gender differences in repair mechanisms of chronic cholangiopathies with progressive fibrosis. Journal Of Hepatology 2023, 78: s78. DOI: 10.1016/s0168-8278(23)00552-4.Peer-Reviewed Original Research